Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glutamine + transforming growth factor-beta 2 is an oral nutritional combination developed by Nestlé Health Science (Société des Produits Nestlé) for the prevention of chemotherapy-induced toxicities, particularly gastrointestinal side effects like diarrhea and mucositis in patients with digestive cancers. The formulation leverages the synergistic effects of L-glutamine, which serves as a primary energy source for enterocytes and supports intestinal mucosal integrity, and Transforming Growth Factor-beta 2 (TGF-beta 2), a potent anti-inflammatory cytokine that regulates epithelial cell proliferation and suppresses the production of pro-inflammatory mediators. By maintaining the gut barrier and modulating the local immune response, the formula aims to reduce the severity of mucosal damage caused by cytotoxic agents such as 5-fluorouracil and irinotecan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glutamine + transforming growth factor-beta 2.